Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EPS (Weighted Average and Diluted) (2020 - 2025)

Crinetics Pharmaceuticals (CRNX) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at -$1.3 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 49.43% year-over-year to -$1.3; the TTM value through Dec 2025 reached -$4.95, down 34.15%, while the annual FY2025 figure was -$4.95, 34.15% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.3 in Q4 2025 per CRNX's latest filing, up from -$1.38 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.73 in Q3 2021 and bottomed at -$1.38 in Q3 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.93, with a median of -$0.88 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): rose 5.88% in 2024, then crashed 49.43% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.8 in 2021, then dropped by 3.55% to -$0.83 in 2022, then dropped by 6.02% to -$0.88 in 2023, then grew by 1.14% to -$0.87 in 2024, then crashed by 49.43% to -$1.3 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$1.3 in Q4 2025, -$1.38 in Q3 2025, and -$1.23 in Q2 2025.